SEC v. Dishant Gupta, No. LR-26364, District of Massachusetts (July 30, 2025) — Press Release
raw: Dishant Gupta
Dishant Gupta, No. 1:24-cv-12316 (July 30, 2025)
summary
Former Ipsen Biopharmaceuticals employee Dishant Gupta obtained a final judgment for insider trading on Epizyme, Inc. shares, resulting in a $296,879 financial penalty and a prison sentence.
paragraph
Dishant Gupta was charged with violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 for insider trading ahead of Ipsen Biopharmaceuticals' acquisition of Epizyme, Inc. He realized approximately $260,000 in illicit profits by trading on material non-public information. The court ordered a total payment of $296,879 in disgorgement and interest, which will be offset by a parallel criminal forfeiture.
narrative
The SEC obtained a final judgment against Dishant Gupta, a former employee of Ipsen Biopharmaceuticals, for insider trading related to his employer's acquisition of Epizyme, Inc. Gupta used material non-public information to purchase Epizyme shares, realizing approximately $260,000 in illicit profits. He was charged with violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5. The court ordered Gupta to pay $260,078 in disgorgement and $36,801 in prejudgment interest, totaling $296,879. This amount will be offset by a forfeiture ordered in a parallel criminal proceeding where Gupta pleaded guilty and received a two-month prison sentence. Additionally, Gupta is enjoined from future securities violations and prohibited from serving as a public company officer or director.
Classified insider-trading(confidence 100%). EDGAR detection: forms 4/3/5/144· recall 81% / precision 19%. detection rule →
Parties
Securities and Exchange CommissionDishant Gupta
Keywords
guptadishant guptasecsecurities exchangedishantexchange commissioninsider tradingentered finalfinal consentgupta violatingsecuritiesexchangejulyfinalagainst
Exhibits & Attached Documents (1)
Extracted insights
Dollar amounts 5
- $297K $296,879 $100K–$1M
- $260K $260,078 $100K–$1M
- $260K $260,078 $100K–$1M
- $260K $260,000 $100K–$1M
- $37K $36,801 $10K–$100K
Entities 7
- person dishant gupta
- company epizyme, inc.
- person epizyme shares
- company ipsen biopharmaceuticals, inc.
- agency sec investigation
- agency Securities and Exchange Commission
- court united states district court for the district of massachusetts
Triples 13
- SEC Obtains Final Judgment Against Dishant Gupta
- United States District Court For The District Of Massachusetts Entered Final Consent Judgment Against Dishant Gupta
- SEC Charged Dishant Gupta
- Ipsen Biopharmaceuticals, Inc. Agreed To Acquire Epizyme, Inc.
- Gupta Purchased Epizyme Shares
- Gupta Realized $260,000 In Illicit Profits
- SEC Charged Gupta With Violating Section 10(b)
- Court Enjoined Gupta From Violating Provisions
- Court Found Gupta Liable For Disgorgement
- Gupta Pleaded Guilty In Criminal Proceeding
- Gupta Was Sentenced To Two Months In Prison
- Nicholas Kararasimas, Melissa Coppola, And Sandeep Satwalekar Conducted SEC Investigation
- Thomas P. Smith, Jr. Supervised Investigation
PDF (from attached: judgment)
Text layers
Extracted body text (2,241c)
U.S. SECURITIES AND EXCHANGE COMMISSION Litigation Release No. 26364 / July 30, 2025 Securities and Exchange Commission v. Dishant Gupta, No. 1:24-cv-12316 (D. Mass. filed Sept. 10, 2024) SEC Obtains Final Judgment Against Former Pharmaceutical Employee Charged with Insider Trading On July 29, 2025, the United States District Court for the District of Massachusetts entered a final consent judgment against New Jersey resident Dishant Gupta. The SEC previously charged Gupta with insider trading ahead of an announcement that Ipsen Biopharmaceuticals, Inc., then Gupta’s employer, had agreed to acquire Epizyme, Inc. The SEC’s complaint, filed on September 10, 2024, alleged that Gupta became aware of Ipsen’s interest in acquiring Epizyme or its premier drug months before the transaction was publicly announced. According to the complaint, Gupta purchased Epizyme shares while aware of that material non-public information and, after the announcement was made, sold the shares and realized approximately $260,000 in illicit profits. The SEC charged Gupta with violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. On September 24, 2024, the court entered a bifurcated consent judgment that enjoined Gupta from violating the charged provisions and prohibited him from serving as an officer or director of a public company. On July 29, 2025, the court entered a final consent judgment that, in addition to including the above relief, found Gupta liable for disgorgement of $260,078 and prejudgment interest of $36,801, for a total of $296,879, payment of which will be offset by $260,078, the amount of forfeiture ordered against Gupta in a parallel criminal proceeding, United States v. Gupta, 24-cr-10279 (JEK) (D. Mass.), in which Gupta pleaded guilty and was sentenced to two months in prison. The SEC’s investigation was conducted by Nicholas Karasimas, Melissa Coppola, and Sandeep Satwalekar, and supervised by Thomas P. Smith, Jr., all of the New York Regional Office. The litigation was led by Mr. Karasimas and Mr. Satwalekar. The SEC appreciates the assistance of the United States Attorney’s Office for the District of Massachusetts, the FBI, and the Financial Industry Regulatory Authority.
OCR text (2,241c · html-text · 99% conf)
U.S. SECURITIES AND EXCHANGE COMMISSION Litigation Release No. 26364 / July 30, 2025 Securities and Exchange Commission v. Dishant Gupta, No. 1:24-cv-12316 (D. Mass. filed Sept. 10, 2024) SEC Obtains Final Judgment Against Former Pharmaceutical Employee Charged with Insider Trading On July 29, 2025, the United States District Court for the District of Massachusetts entered a final consent judgment against New Jersey resident Dishant Gupta. The SEC previously charged Gupta with insider trading ahead of an announcement that Ipsen Biopharmaceuticals, Inc., then Gupta’s employer, had agreed to acquire Epizyme, Inc. The SEC’s complaint, filed on September 10, 2024, alleged that Gupta became aware of Ipsen’s interest in acquiring Epizyme or its premier drug months before the transaction was publicly announced. According to the complaint, Gupta purchased Epizyme shares while aware of that material non-public information and, after the announcement was made, sold the shares and realized approximately $260,000 in illicit profits. The SEC charged Gupta with violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. On September 24, 2024, the court entered a bifurcated consent judgment that enjoined Gupta from violating the charged provisions and prohibited him from serving as an officer or director of a public company. On July 29, 2025, the court entered a final consent judgment that, in addition to including the above relief, found Gupta liable for disgorgement of $260,078 and prejudgment interest of $36,801, for a total of $296,879, payment of which will be offset by $260,078, the amount of forfeiture ordered against Gupta in a parallel criminal proceeding, United States v. Gupta, 24-cr-10279 (JEK) (D. Mass.), in which Gupta pleaded guilty and was sentenced to two months in prison. The SEC’s investigation was conducted by Nicholas Karasimas, Melissa Coppola, and Sandeep Satwalekar, and supervised by Thomas P. Smith, Jr., all of the New York Regional Office. The litigation was led by Mr. Karasimas and Mr. Satwalekar. The SEC appreciates the assistance of the United States Attorney’s Office for the District of Massachusetts, the FBI, and the Financial Industry Regulatory Authority.